Published in Cancer Gene Ther on June 24, 2011
A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer (FP253-GDEPT) | NCT00625430
Oncolytic viral therapy for pancreatic cancer: current research and future directions. Oncolytic Virother (2014) 0.95
Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther (2013) 0.95
Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. Mol Ther (2012) 0.93
A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma. Hum Gene Ther (2013) 0.93
Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther (2013) 0.90
In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer Chemother Pharmacol (2012) 0.85
Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins. J Virol (2011) 0.84
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol (2013) 0.84
MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus. Cancer Gene Ther (2014) 0.82
Measles to the Rescue: A Review of Oncolytic Measles Virus. Viruses (2016) 0.79
High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus. Cancer Gene Ther (2014) 0.78
In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models. Gene Ther (2014) 0.77
Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol (2016) 0.77
PRE-CLINICAL AND CLINICAL VALIDATION OF AN ANTI-CANCER MODALITY THAT ABLATES REFRACTORY, LOW GROWTH FRACTION TUMORS. Trans Am Clin Climatol Assoc (2016) 0.75
Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics. J Gastrointest Oncol (2016) 0.75
Potential and clinical translation of oncolytic measles viruses. Expert Opin Biol Ther (2017) 0.75
Advances in the design and development of oncolytic measles viruses. Oncolytic Virother (2015) 0.75
Oncolytic viruses against cancer stem cells: A promising approach for gastrointestinal cancer. World J Gastroenterol (2016) 0.75
Fighting Cancer with Mathematics and Viruses. Viruses (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Pancreatic cancer. N Engl J Med (2010) 13.88
Rescue of measles viruses from cloned DNA. EMBO J (1995) 7.87
The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell (1993) 7.71
Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol (1993) 7.27
The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol (1993) 6.38
SLAM (CDw150) is a cellular receptor for measles virus. Nature (2000) 6.07
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50
Oncolytic viruses in cancer therapy. Cancer Lett (2007) 2.45
Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol (2004) 2.42
Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol (2005) 2.40
Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol (1999) 2.34
Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res (1998) 2.32
Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res (2002) 2.18
High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res (2004) 2.14
Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res (2003) 2.12
High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res (2009) 1.49
Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther (2010) 1.44
Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res (2007) 1.41
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology (2006) 1.40
Antibody-targeted cell fusion. Nat Biotechnol (2004) 1.39
Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res (2009) 1.36
Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther (2002) 1.29
Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate (2009) 1.25
Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas (2005) 1.25
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther (2008) 1.24
Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer (2005) 1.24
An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther (2007) 1.21
A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat (2006) 1.21
Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol (1998) 1.20
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther (2006) 1.20
Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol (2003) 1.18
Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin Cancer Res (2004) 1.12
Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc (2007) 1.08
Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate (2007) 1.07
Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene. Cancer Res (2004) 1.03
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate (2009) 1.00
Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens. J Urol (2003) 0.99
Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther (2010) 0.99
Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol (1999) 0.97
Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res (1995) 0.94
Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther (2007) 0.93
Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology (2000) 0.89
Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin Cancer Res (1997) 0.87
PNP anticancer gene therapy. Curr Top Med Chem (2005) 0.87
Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med (2004) 0.86
Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Ther (2004) 0.83
Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration. Cancer Res (2005) 0.83
Targeting gene therapy for hepatocarcinoma cells with the E. coli purine nucleoside phosphorylase suicide gene system directed by a chimeric alpha-fetoprotein promoter. Cancer Lett (2008) 0.83
Development of gene therapy in association with clinically used cytotoxic deoxynucleoside analogues. Cancer Gene Ther (2009) 0.82
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Signals regulating hepatitis B surface antigen transcription. Nature (1983) 5.02
Replication strategy of human hepatitis B virus. J Virol (1987) 4.42
Hepatitis B virus transcription in the infected liver. EMBO J (1984) 3.44
Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol (1998) 3.27
Measles virus spread and pathogenesis in genetically modified mice. J Virol (1998) 2.84
Cloned HBV DNA causes hepatitis in chimpanzees. Nature (1982) 2.80
Ilizarov treatment of tibial nonunions with bone loss. Clin Orthop Relat Res (1989) 2.71
Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J (1987) 2.67
Structure of the FMDV translation initiation site and of the structural proteins. Nucleic Acids Res (1983) 2.58
Biased hypermutation of viral RNA genomes could be due to unwinding/modification of double-stranded RNA. Cell (1989) 2.54
A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. EMBO J (1998) 2.48
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis (2010) 2.38
Retracted Infectious measles virus from cloned cDNA. EMBO J (1990) 2.36
Antibody and HIV-1 gp120 recognition of CD4 undermines the concept of mimicry between antibodies and receptors. Nature (1992) 2.27
Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 2.20
A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. Am J Pathol (1999) 2.16
Preferential initiation at the second AUG of the measles virus F mRNA: a role for the long untranslated region. Virology (1995) 1.96
Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in vitro. Proc Natl Acad Sci U S A (1996) 1.89
The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. J Virol (2001) 1.88
Measles virus envelope glycoproteins hetero-oligomerize in the endoplasmic reticulum. J Biol Chem (2001) 1.87
Expression of defective measles virus genes in brain tissues of patients with subacute sclerosing panencephalitis. J Virol (1986) 1.84
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum Gene Ther (2001) 1.83
A novel expression selection approach allows precise mapping of the hepatitis B virus enhancer. Nucleic Acids Res (1985) 1.82
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood (2001) 1.82
Retracted Functional and nonfunctional measles virus matrix genes from lethal human brain infections. J Virol (1991) 1.82
Expression of hepatitis B antigens with a simian virus 40 vector. J Virol (1984) 1.80
Measles virus phosphoprotein retains the nucleocapsid protein in the cytoplasm. Virology (1991) 1.77
Chimeric measles viruses with a foreign envelope. J Virol (1998) 1.75
Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus (1999) 1.70
Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol (2004) 1.68
Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice. Proc Natl Acad Sci U S A (1996) 1.68
Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. Nephrol Dial Transplant (2001) 1.67
Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer (2007) 1.67
Systemic lupus erythematosus and pregnancy: a prospective study. Clin Exp Rheumatol (1993) 1.60
Detection of an element of the SV40 late promoter in vectors used for expression studies in COS cells. EMBO J (1983) 1.57
Restricted expression of T cell receptor V beta but not V alpha genes in rheumatoid arthritis. Eur J Immunol (1991) 1.55
Cell entry by measles virus: long hybrid receptors uncouple binding from membrane fusion. J Virol (1996) 1.51
Transplacental uptake of glucose is decreased in embryonic lethal connexin26-deficient mice. J Cell Biol (1998) 1.49
Accumulated measles virus mutations in a case of subacute sclerosing panencephalitis: interrupted matrix protein reading frame and transcription alteration. Virology (1986) 1.49
Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J Virol (2000) 1.48
HLA-DR antigens and anticardiolipin antibodies in northern Italian systemic lupus erythematosus patients. Arthritis Rheum (1988) 1.48
Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol (2000) 1.44
Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases--a multicentre prospective study. Rheumatology (Oxford) (2007) 1.44
Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice. J Clin Invest (2001) 1.43
Subacute sclerosing panencephalitis is typically characterized by alterations in the fusion protein cytoplasmic domain of the persisting measles virus. Virology (1992) 1.39
Generation and properties of measles virus mutations typically associated with subacute sclerosing panencephalitis. Ann N Y Acad Sci (1994) 1.39
Characterization of a region of the measles virus hemagglutinin sufficient for its dimerization. J Virol (2000) 1.38
A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol (1999) 1.33
Roles of macrophages in measles virus infection of genetically modified mice. J Virol (2001) 1.33
Mapping of the primary binding site of measles virus to its receptor CD46. J Biol Chem (1997) 1.32
Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol (2001) 1.31
Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum (1991) 1.28
Involvement of the cytotoxic/suppressor T-cell subset in liver tissue injury of patients with acute and chronic liver diseases. Gastroenterology (1983) 1.26
Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res (2000) 1.24
Measles virus glycoprotein complex assembly, receptor attachment, and cell entry. Curr Top Microbiol Immunol (2009) 1.24
The cellular receptor (CD4) of the human immunodeficiency virus is expressed on neurons and glial cells in human brain. J Exp Med (1987) 1.23
Local production of interleukin-4 during radiation-induced pneumonitis and pulmonary fibrosis in rats: macrophages as a prominent source of interleukin-4. Am J Respir Cell Mol Biol (1997) 1.22
Anti-phospholipid and anti-mitochondrial type M5 antibodies in systemic lupus erythematosus. Clin Exp Rheumatol (1986) 1.22
In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein. J Virol (2000) 1.20
Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. J Neurol Sci (2001) 1.20
Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood (1996) 1.20
Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res (2000) 1.20
Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res (2000) 1.19
Role of N-linked oligosaccharide chains in the processing and antigenicity of measles virus haemagglutinin protein. J Gen Virol (1994) 1.18
A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol (1998) 1.17
Induction of Fc epsilon R2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and gamma interferon. J Exp Med (1989) 1.16
Membrane cofactor protein (MCP; CD46) expression in transgenic mice. Clin Exp Immunol (2001) 1.16
A procedure for selective full length cDNA cloning of specific RNA species. Nucleic Acids Res (1987) 1.15
Measles virus spread by cell-cell contacts: uncoupling of contact-mediated receptor (CD46) downregulation from virus uptake. J Virol (1999) 1.14
Restriction of measles virus gene expression in acute and subacute encephalitis of Lewis rats. Virology (1989) 1.13
Influence of N-linked oligosaccharide chains on the processing, cell surface expression and function of the measles virus fusion protein. J Gen Virol (1995) 1.12
Predominance of 'memory' phenotype within CD4+ and CD8+ lymphocyte subsets after allogeneic BMT. Bone Marrow Transplant (1993) 1.11
Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer (2001) 1.10
Occurrence of IgE-bearing epidermal Langerhans cells in atopic eczema: a study of the time course of the lesions and with regard to the IgE serum level. J Invest Dermatol (1989) 1.09
Recombinant measles virus requiring an exogenous protease for activation of infectivity. J Gen Virol (2000) 1.09
Suppression of graft versus host reaction by univalent anti-immunoglobulin antibody. Nat New Biol (1971) 1.09
IgE-dependent antigen focusing by human B lymphocytes is mediated by the low-affinity receptor for IgE. Eur J Immunol (1990) 1.08
Th2 cells as effectors in postirradiation pulmonary damage preceding fibrosis in the rat. Int J Radiat Biol (1999) 1.07
A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood (1996) 1.07
Treatment of genu varum in medial compartment osteoarthritis of the knee using the Ilizarov method. Orthop Clin North Am (1994) 1.06
Ineffective expression of CD40 ligand on cord blood T cells may contribute to poor immunoglobulin production in the newborn. Eur J Immunol (1994) 1.06
Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity. Cancer Res (1986) 1.05
Idiopathic eosinophilic pneumonia and pregnancy: report of a case. Int Arch Allergy Immunol (1995) 1.03
A rapid and simple method for reversing the inhibitory effect of heparin on PCR for HLA class II typing. PCR Methods Appl (1993) 1.02
CD70 expression on T-cell subpopulations: study of normal individuals and patients with chronic immune activation. Immunol Lett (1997) 1.02
Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia (2011) 1.01
Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther (2009) 1.01
Lymphocytes with T-cell markers cooperate with IgG antibodies in the lysis of human tumour cells. Nature (1977) 1.00
Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients. Clin Exp Rheumatol (2001) 1.00
Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther (2010) 0.99
Selective expression of a subset of measles virus receptor-competent CD46 isoforms in human brain. Virology (1996) 0.99
Allergy-associated I epsilon and Ec epsilon receptor II (CD23b) genes activated via binding of an interleukin-4-induced transcription factor to a novel responsive element. Eur J Immunol (1993) 0.99
Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood (1991) 0.99
Lengthening of the forearm by the Ilizarov technique. Clin Orthop Relat Res (1990) 0.99
Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". Autoimmun Rev (2005) 0.97